• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Entero Cuts Staff, Vacates Office, Pauses R&D Amid Financial Troubles

    FIERCE BIOTECH

    First Wave BioPharma Changes Name to Entero Therapeutics

    GLOBENEWSWIRE

    First Wave BioPharma Rebrands to Entero Therapeutics

    CONTRACT PHARMA

    First Wave BioPharma $1.1M At-The-Market Equity Raise

    GLOBENEWSWIRE

    First Wave And Celiac Journey Nasdaq Celiac Awareness Event

    GLOBENEWSWIRE

    First Wave BioPharma Paper in Celiac Disease Journal

    GLOBENEWSWIRE

    First Wave BioPharma CEO to Present at Planet MicroCap

    GLOBENEWSWIRE

    First Wave CEO At Longwood Healthcare Leaders Conf 2024

    GLOBENEWSWIRE

    First Wave Announces Two Abstracts on Celiac Disease Research for Presentation

    GLOBENEWSWIRE

    First Wave Announces Completion of Combination with ImmunogenX

    GLOBENEWSWIRE

    First Wave to Participate In ˜Fireside Chat at the 36th Annual Roth Conference

    GLOBENEWSWIRE

    First Wave BioPharma, Inc. to Raise Approximately $4.0 Million of Gross Proceeds

    GLOBENEWSWIRE

    First Wave BioPharma CEO to Present at the BIO CEO & Investor Conference 2024

    GLOBENEWSWIRE

    First Wave BioPharma to Present at the DealFlow MicroCap Conference

    GLOBENEWSWIRE

    First Wave BioPharma CEO to Present at the Sequire Summit 2024 in Puerto Rico

    PRESS RELEASE

    First Wave BioPharma Chairman and CEO Issues Letter to Shareholders

    GLOBENEWSWIRE

    First Wave BioPharma Announces Streamlining of Clinical Pipeline

    GLOBENEWSWIRE

    First Wave Bio Announces Exercise of Warrants and Issuance of New Warrants

    GLOBENEWSWIRE

    First Wave BioPharma Announces Entry into Term Sheet for Business Combination

    GLOBENEWSWIRE

    First Wave BioPharma Announces 1-for-20 Reverse Stock Split

    GLOBENEWSWIRE

    First Wave to Participate in BIO Partnering @JPM During œJ.P. Morgan Week 2024

    GLOBENEWSWIRE

    First Wave CEO James Sapirstein to Moderate Panel Discussion at Conference

    GLOBENEWSWIRE

    Date Announced for First Wave CEO James Sapirstein™s Presentation

    GLOBENEWSWIRE

    First Wave BioPharma CEO James Sapirstein to Present at Conference

    GLOBENEWSWIRE

    First Wave BioPharma To Present at the BIO Investor Forum

    GLOBENEWSWIRE

    First Wave BioPharma Announces Agreement for Capeserod from Sanofi

    GLOBENEWSWIRE

    First Wave BioPharma Announces Exercise of Warrants

    GLOBENEWSWIRE

    First Wave BioPharma to Participate in the H.C. Wainwright 25th Conference

    GLOBENEWSWIRE

    First Wave BioPharma, Inc. Announces Pricing of $2.1 Million Public Offering

    GLOBENEWSWIRE

    Gut punch: First Wave`s challenger to AbbVie fails phase 2 again

    FIERCE BIOTECH

    First Wave BioPharma Chairman and CEO Issues Letter to Stockholders

    GLOBENEWSWIRE

    First Wave Announces Final Patient Dosed Ph2 SPAN Trial Adrulipase Formulation

    GLOBENEWSWIRE

    First Wave BioPharma Strengthens Intellectual Property Estate

    GLOBENEWSWIRE

    First Wave BioPharma to Attend the 36th National Cystic Fibrosis Education

    GLOBENEWSWIRE

    First Wave BioPharma Reaches Enrollment Target for Phase 2 SPAN Adrulipase Trial

    GLOBENEWSWIRE

    First Wave BioPharma Announces Exercise of Warrants

    GLOBENEWSWIRE

    First Wave BioPharma CEO James Sapirstein to Present at 2023 BIO Conference

    GLOBENEWSWIRE

    First Wave completes patient screening in trial of cystic fibrosis therapy

    CLINICAL TRIALS ARENA

    First Wave Completes Screening For PII Span Adrulipase Trial in Cystic Fibrosis

    GLOBENEWSWIRE

    First Wave BioPharma to Participate in EF Hutton Inaugural Global Conference

    GLOBENEWSWIRE

    First Wave Biopharma Exceeds 50% Enrollment Target for Phase 2 Span Adrulipase

    GLOBENEWSWIRE

    First Wave Announces $4.0 Million Private Placement Priced under Nasdaq Rules

    GLOBENEWSWIRE

    First Wave BioPharma Announces Second Patient Dosed in Phase 2 SPAN Trial

    GLOBENEWSWIRE

    First Wave Announces First Patient Dosed in Phase 2 SPAN Trial of Adrulipase

    GLOBENEWSWIRE

    First Wave to Participate in Fireside Chat at the 35th Annual Roth Conference

    GLOBENEWSWIRE

    First Wave Announces PII Adrulipase Trial Data to be Presented at DDW

    GLOBENEWSWIRE

    First Wave BioPharma Chairman and CEO Issues Letter to Stockholders

    GLOBENEWSWIRE

    First Wave Regains Compliance With Nasdaq`s Minimum Bid Price Requirement

    GLOBENEWSWIRE

    First Wave Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial

    GLOBENEWSWIRE

    First Wave Announces Initiation of PII Trial Investigating Enhanced Adrulipase

    GLOBENEWSWIRE

    First Wave BioPharma to Present at the BIO CEO & Investor Conference

    GLOBENEWSWIRE

    First Wave Announces Expansion of Adrulipase Intellectual Property Portfolio

    GLOBENEWSWIRE

    First Wave BioPharma to Present at Sequire Biotechnology Conference

    GLOBENEWSWIRE

    First Wave BioPharma Announces Results of Special Meeting of Stockholders

    GLOBENEWSWIRE

    First Wave BioPharma Provides Update on IND Filing For PII Trial of Adrulipase

    GLOBENEWSWIRE

    First Wave BioPharma Announces Adjournment of Special Meeting

    GLOBENEWSWIRE

    First Wave BioPharma to Participate in BIO Partnering @ JPM During

    GLOBENEWSWIRE

    First Wave BioPharma Announces Initial Clinical Sites for its Phase 2 Trial

    GLOBENEWSWIRE

    First Wave BioPharma Files iNDA Microgranule Delivery Formulation of Adrulipase

    GLOBENEWSWIRE

    First Wave Announces Distribution of Series F Preferred Stock to Holders

    GLOBENEWSWIRE

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.